LUMOXITI

This brand name is authorized in United States. It is also authorized in Brazil, Estonia, Lithuania, Poland.

Active ingredients

The drug LUMOXITI contains one active pharmaceutical ingredient (API):

1	Moxetumomab pasudotox UNII 2NDX4B6N8F - MOXETUMOMAB PASUDOTOX
	Moxetumomab pasudotox is a CD22-directed cytotoxin. Moxetumomab pasudotox binds CD22 on the cell surface of B-cells and is internalized. Moxetumomab pasudotox internalization results in ADP-ribosylation of elongation factor 2, inhibition of protein synthesis, and apoptotic cell death.

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
LUMOXITI Powder for solution for injection	MPI, US: SPL/PLR	FDA, National Drug Code (US)
LUMOXITI Powder for concentrate solution for solution for infusion	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01FB02	Moxetumomab pasudotox	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FB CD22 (Clusters of Differentiation 22) inhibitors
Discover more medicines within L01FB02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	502321040034305, 502321040034405
EE	Ravimiamet	1840801, 1840812
LT	Valstybinė vaistų kontrolės tarnyba	1092131, 1092132
PL	Rejestru Produktów Leczniczych	100448631
US	FDA, National Drug Code	0310-4700, 73380-4700